| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 10/03/2006 | US7115758 Vitamin D derivatives with cyclic substructures in the side chains, process and intermediate products for their production, and the use for the production of pharmaceutical agents |
| 10/03/2006 | US7115739 Triazole compounds useful as protein kinase inhibitors |
| 10/03/2006 | US7115720 Structurally distinct radionuclide complexes of multinitrogen heterocycles having phosphonic acid groups that target bone, and thus, are useful as imaging and therapeutic agents (e.g., for bone marrow suppression, cancer, bone pain) |
| 10/03/2006 | US7115662 Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives |
| 10/03/2006 | US7115661 Methods and compositions for mitigating pain |
| 10/03/2006 | US7115637 Inhibitors of p38 |
| 10/03/2006 | US7115635 Benzylpiperidine compound |
| 10/03/2006 | US7115630 Metabotropic glutamate receptor antagonists |
| 10/03/2006 | US7115623 1,8-Naphthyridin-2(1H)-one derivatives; antiasthmatic, antihistamine, and bronchodilator agents; nontoxic, side effect reduction |
| 10/03/2006 | US7115616 Pyrimidinone compounds |
| 10/03/2006 | US7115615 Antitumour agents as enzyme inhibitors of the nonreceptor tyrosine protein kinases involved in the signal transduction; noninvasive; antimetatic and -carcinogenic agents; derivatives of 4-(1,3-benzo-dioxol-4-yl)amino-)quinazoline |
| 10/03/2006 | US7115613 Compound of fused nitrogen containing heterocyclic ring, useful for treating prostate and angiogenic disorders |
| 10/03/2006 | US7115602 Antiinflammatory agents; respiratory system disorders; autoimmune disease |
| 10/03/2006 | US7115599 Guanylate cyclase stimulant; cardiovascular disorders; thrombosis; antiischemic agents; sexual disorders; antiinflammatory agents; central nervous system disorders |
| 10/03/2006 | US7115597 Tyrosine kinase inhibitors |
| 10/03/2006 | US7115589 Phosphorus-containing moietys; kinase inhibitors; improve balance of bone growth relative to bone resorption; inhibit PTH-induced bone resorption; cytotoxic or growth inhibitory effect on cancer cell lines |
| 10/03/2006 | US7115585 Compositions for treating epithelial and retinal tissue diseases |
| 10/03/2006 | US7115573 Prodrug compounds with an isoleucine |
| 10/03/2006 | US7115565 Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| 10/03/2006 | US7115395 DNAs encoding guinea pig histamine receptors of the H4 subtype |
| 10/03/2006 | US7115392 Polynucleotides encoding human vascular endothelial growth factor 2 |
| 10/03/2006 | US7115252 For restoration and maintenance of gingival and periodontal health; antiplaque/antitar agents; mouthwash |
| 10/03/2006 | US7115250 Heating erectile dysfunction drug to vaporize; cooling to form condensation aerosol; drug delivery |
| 10/03/2006 | CA2288241C Use of tetrahydropyridine derivatives to prepare medicines for treating diseases causing demyelination |
| 10/03/2006 | CA2279535C Dermatan disulfate, an inhibitor of thrombin generation and complement activation |
| 10/03/2006 | CA2249348C Preparation containing a combination of 5-methylisoxazole-4-carboxylic acid-(4-trifluoromethyl)-anilide and n-(4-trifluoromethylphenyl)2-cyano-3-hydroxycrotonic acid amide |
| 10/03/2006 | CA2212440C Pharmaceutical preparations for tnf inhibition |
| 09/28/2006 | WO2006102645A1 Biaryl derived amide modulators of vanilloid vr1 receptor |
| 09/28/2006 | WO2006102112A2 Prokineticin 1 receptor |
| 09/28/2006 | WO2006102079A1 N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase |
| 09/28/2006 | WO2006101860A1 Novel thiophene sulfoximines for treating complement-mediated diseases and conditions |
| 09/28/2006 | WO2006101454A1 Benzothiophene derivatives: preparation and pharmaceutical applications |
| 09/28/2006 | WO2006101434A1 NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1’ RECEPTOR LIGANDS |
| 09/28/2006 | WO2006101422A1 Phenyl-containing n-acyl amine and aminoacid derivatives, methods for the production thereof, a pharmaceutical composition and the use thereof |
| 09/28/2006 | WO2006101245A1 N-substituted-n-(4-piperidinyl) amide derivative |
| 09/28/2006 | WO2006101104A1 Agent for treatment of arthritis |
| 09/28/2006 | WO2006100520A1 2,3-substituted fused pyrimidin-4(3h)-ones as vr1 antagonists |
| 09/28/2006 | WO2006100213A1 Composition comprising a combined thromboxane receptor antagonist and thromboxane synthase inhibitor and a cox-2 inhibitor |
| 09/28/2006 | WO2006100099A1 6, 7, 8, 9-tetrahydro-5-amino-5h-benzocyclohepten-6-ol derivatives and related compounds used as anti-inflammatory agents |
| 09/28/2006 | WO2006100095A1 Substituted carboxamides method for production and use thereof as tnf-alpha release inhibitors |
| 09/28/2006 | WO2006100019A1 Polymorphic form of 6- (4-chlorophenyl) -2, 2-dimethyl-7-phenyl-2, 3-dihydro-lh-pyrrolizin-5-ylacetic acid |
| 09/28/2006 | WO2006099684A1 Copper complexes |
| 09/28/2006 | WO2006099681A1 Isoflavonoid dimers |
| 09/28/2006 | WO2006099677A1 Metal complexes |
| 09/28/2006 | WO2006067867A8 Cell adhesion factor expression inhibitor |
| 09/28/2006 | WO2006047503A3 Inhibitors of c-fms kinase |
| 09/28/2006 | WO2005021776A3 METHODS OF USING MAMMALIAN RNase H AND COMPOSITIONS THEREOF |
| 09/28/2006 | US20060217561 Synthesis of substituted thiazoline carboxylic acids |
| 09/28/2006 | US20060217557 Polymorphic form XVI of fexofenadine hydrochloride |
| 09/28/2006 | US20060217531 Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
| 09/28/2006 | US20060217530 Active against C5a receptors on polymorphonuclear leukocytes and macrophages; peptidomimetics; for treatment of inflammation |
| 09/28/2006 | US20060217444 Tramadol for the treatment of functional gastrointestinal disorders |
| 09/28/2006 | US20060217424 Compounds for the inhibition of nitric oxide synthase |
| 09/28/2006 | US20060217407 Compositions and Formulations of 9-Nitrocamptothecin Polymorphs and Methods of Use Therefor |
| 09/28/2006 | US20060217406 7-(3-Pyridyl)-1,7-diazaspiro-[4,4]nonane and its salts and proline amides; capable of affecting nicotinic cholinergic receptors, e.g., as modulators of specific nicotinic receptor subtypes; neuroprotective agents |
| 09/28/2006 | US20060217388 Phthalazine derivatives for treating inflammatory diseases |
| 09/28/2006 | US20060217374 {6-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-benzo[b]thiophen-3-yl}-acetic acid; antidiabetic agent; metabolic Syndrome, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis; lowering fibrinogen, increasing HDL levels |
| 09/28/2006 | US20060217373 Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same |
| 09/28/2006 | US20060217364 Beta-lactamyl vasopressin V1a antagonists |
| 09/28/2006 | US20060217349 Having antiinflammatory, anti-pyretic and anti-diarrheal properties |
| 09/28/2006 | US20060217339 Breast cancer, prostate cancer, brain cancer, head and neck cancer, myeloma, melanoma, leukemia and lymphoma; promotion of apoptosis; may have phosphorothioate, 2'-O-(2-methoxyethyl) sugar, and/or 5-methyl cytosine modifications; useful prophylactically, and as clinical research and diagnostic tools. |
| 09/28/2006 | US20060217309 Novel cyclosporine analog formulations |
| 09/28/2006 | US20060216777 Immobilization on solid support |
| 09/28/2006 | US20060216745 Polynucleotides, expression vectors, and host cells for culturing truncated tryptophanyl-tRNA synthetase polypeptides having chemokine activity; bioassay; drug screening; antitumor agents, antimetastasis agents |
| 09/28/2006 | US20060216739 Insulin-like growth factor binding protein |
| 09/28/2006 | US20060216349 Ibuprofen composition |
| 09/28/2006 | US20060216340 drug delivery at least two-day additional dosing interval; allows for reduced plasma concentrations over a prolonged time period while still providing effective pain management; transdermal delivery system maximizes the dosage interval |
| 09/28/2006 | US20060216307 Vaccine composition |
| 09/28/2006 | US20060216301 Kdr peptides and vaccines containing the same |
| 09/28/2006 | US20060216244 Delivery of compounds for the treatment of parkinson's through an inhalation route |
| 09/28/2006 | US20060216243 Delivery of Beta-Blockers Through An Inhalation Route |
| 09/28/2006 | DE102006012107A1 Verwendung von Estern der Angelicasäure als antiphlogistischen Wirkstoff, sowie antiphlogistische Zubereitungen The use of esters of angelic acid as anti-inflammatory active substance, as well as anti-inflammatory preparations |
| 09/28/2006 | DE102005014090A1 5H-Benzocycloheptenderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer 5H-Benzocycloheptenderivate, processes for their preparation and their use as anti-inflammatories |
| 09/28/2006 | DE102005014089A1 Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer Tetrahydronaphthalene derivatives, processes for their preparation and their use as anti-inflammatories |
| 09/28/2006 | DE102005012971A1 Polymorphe Form von 6-(4-Chlorphenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl-essigsäure Polymorphic form of 6- (4-chlorophenyl) -2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl-acetic acid |
| 09/28/2006 | CA2602583A1 Biaryl derived amide modulators of vanilloid vr1 receptor |
| 09/28/2006 | CA2602545A1 Phenyl-n-acyl derivatives of amines and amino acids, a process for the preparation thereof, a pharmaceutical composition and the use thereof |
| 09/28/2006 | CA2602541A1 Isoflavonoid dimers |
| 09/28/2006 | CA2602395A1 2,3-substituted fused pyrimidin-4(3h)-ones as vr1 antagonists |
| 09/28/2006 | CA2602374A1 Composition comprising a combined thromboxane receptor antagonist and thromboxane synthase inhibitor and a cox-2 inhibitor |
| 09/28/2006 | CA2602224A1 Polymorphic form of 6- (4-chlorophenyl) -2, 2-dimethyl-7-phenyl-2, 3-dihydro-lh-pyrrolizin-5-ylacetic acid |
| 09/28/2006 | CA2601766A1 N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase |
| 09/28/2006 | CA2601523A1 Novel thiophene sulfoximines for treating complement-mediated diseases and conditions |
| 09/28/2006 | CA2600531A1 Pyrimidine compounds and methods of use |
| 09/28/2006 | CA2598969A1 6, 7, 8, 9-tetrahydro-5-amino-5h-benzocyclohepten-6-ol derivatives and related compounds used as anti-inflammatory agents |
| 09/27/2006 | EP1704862A1 2,5-bis(tetrahydroxybutyl)pyrazines for the treatment of osteoarthritis and rheumatoid arthritis |
| 09/27/2006 | EP1704855A2 2-Cyclopenten-1-one and its Derivatives as Inhibitors of the NF-kappa B Factor |
| 09/27/2006 | EP1703905A1 Indole derivatives and use thereof as kinase inhibitors in particular ikk2 inhibitors |
| 09/27/2006 | EP1534687B1 2-phenylamino-4-trifluoromethyl-5-(benzyl- or pyridin-4-ylmethyl)carbamoylpyrimidine derivatives as selective cb2 cannabinoid receptor modulators |
| 09/27/2006 | EP1501826B1 Substituted indoles as alpha-1 agonists |
| 09/27/2006 | EP1383757B1 Antagonists of mcp-1 function and methods of use thereof |
| 09/27/2006 | EP1337521B1 Salts of an isothiazole-4-carboxamide and their use as anti-hyperproliferation agents |
| 09/27/2006 | EP1286967B1 Cyclohexane derivatives and their use as therapeutic agents |
| 09/27/2006 | EP1272907B1 Compliance tracking method |
| 09/27/2006 | EP1196433B1 CYCLIC PEPTIDE DERIVATIVES AS INHIBITORS OF INTEGRIN ALPHA v BETA 6 |
| 09/27/2006 | CN1839133A Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases |
| 09/27/2006 | CN1838964A Treatment and prevention of pulmonary conditions |
| 09/27/2006 | CN1838961A Use of s1p |
| 09/27/2006 | CN1838952A Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases |
| 09/27/2006 | CN1838951A Bicycl 3.1.1]heptane substituted benzimidazolone and quinazolinone derivatives as agonists on human orl1 receptors |